Cerus is a biomedical products company focused on developing and commercializing the INTERCEPT Blood System for blood safety. The INTERCEPT Blood System, which is based on the company's technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company's INTERCEPT Blood System is for use with three blood components: plasma, platelets, and red blood cells. The platelet system and plasma system are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion and the red blood cell system is designed to inactivate blood-borne pathogens in red blood cells donated for transfusion.
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.